06.03.2025 |

BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe

Related items

News, Scientific publicationsVarmX announces publication of non-clinical safety, toxicokinetic and pharmacodynamic data for VMX-C001 in Pharmaceutics
Key HighlightsThe peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in rats and…
NewsVarmX announces reltodecacog alfa (Relto) as the adopted non-proprietary name for VMX-C001
Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for…